Scholars Central

Conference abstractPublished 26 Oct 2015

AVX-470, an Orally-Delivered GI-Targeted anti-TNF Biobetter

Authors: Neil Schauer

Avaxia Biologics, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Avaxia Biologics is a clinical-stage biopharmaceutical company developing gut-targeted biobetter therapeutics. TNF is a clinically validated target in gut inflammation. Discussion will center on Avaxia’s orally-delivered, minimally absorbed anti-TNF biologic drug that acts locally in the GI tract. In contrast to first generation systemically delivered anti-TNFs, AVX-470 has low systemic exposure for greater safety, higher local concentration to drive efficacy, and the convenience of oral administration.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectDentistry & Oral Health
  • BylineArticles whose byline prints “Neil Schauer”